FDA Recalls Nose Better Gel Due to Manufacturing Process Deviations
Ecometics, Inc. is recalling Nose Better Gel nationwide due to manufacturing process deviations (CGMP violations). The firm-initiated voluntary recall affects 37,968 units with lot number 1E253A.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary recall with no reported illnesses or injuries. The hazard is a manufacturing process deviation (CGMP violation), with no specific product defect or contamination identified. Per the rubric, voluntary precautionary recalls with no reported harm are classified as Moderate.
Plain-English summary
Ecometics, Inc. is recalling Nose Better Gel (0.75% Camphor, 0.50% Menthol, 0.50% Allantoin), packaged in 0.46 oz. (13g) metal tubes and distributed nationwide within the United States by Oakhurst Company in Levittown, NY.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations—violations of FDA manufacturing standards. Ecometics, Inc. voluntarily initiated the recall on February 24, 2023, and the FDA classified it as a Class II recall on March 8, 2023.
The affected product has lot number 1E253A with an expiration date of August 2024. A total of 37,968 units in metal tube/folding carton format were subject to the recall. The recall status was terminated on June 21, 2023.
The recalled product
- Product
- Nose Better Gel (0.75% Camphor, 0.50% Menthol, 0.50% Allantoin), packaged in 0.46 oz. (13g) metal tubes, Distributed by: Oakhurst Company Levittown, NY 11756
- Manufacturer
- Ecometics, Inc.
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 1E253A
- Exp. Date AUG-2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27